How 340B cuts will hit cancer programs: 8 notes

Advertisement

CMS has finalized a 2027 outpatient payment rule that cuts Medicare payments for 340B-acquired drugs by roughly a third starting Jan. 1. Cancer programs at 340B hospitals, which administer many of the costliest Medicare Part B drugs, will feel the cut directly.

Released Nov. 4, the rule also accelerates CMS’ recovery of past overpayments to hospitals and extends site-neutral payments to imaging at off-campus hospital departments.

Hospital groups are split on the rule, with America’s Essential Hospitals calling the 340B cuts “an existential threat to essential hospitals” and the Federation of American Hospitals calling the rule “a win for patients.”

Here are eight things oncology leaders should know before Jan. 1:

  1. Medicare will cut payments for 340B drugs from a drug’s average sales price plus 6%, the rate hospitals receive now, to average sales price minus 28%. CMS had proposed average sales price minus 33.4%, based on a survey of hospital drug acquisition costs from Jan. 1 to April 7.

    CMS estimates the cut will reduce payments to 340B hospitals by about $5.45 billion in 2027: $4.35 billion less from Medicare and $1.1 billion less in patient coinsurance.

  2. Eleven cancer hospitals exempt from Medicare’s inpatient prospective payment system will continue receiving average sales price plus 6% in 2027 and beyond, according to the final rule.

    Cancer centers that bill under a larger 340B hospital will be subject to the cut. Drugs with transitional pass-through status, typically recently approved therapies, will also remain at average sales price plus 6%, as will vaccines.

  3. CMS will use the money it saves on 340B drugs to increase payments to hospitals for other outpatient services, such as clinic visits, imaging and procedures. The increase will apply to every hospital paid under the outpatient system, including for-profit hospitals that don’t participate in 340B.

    CMS expects most 340B hospitals to lose more from the drug cut than they gain from the higher rates.

    A KFF analysis projected the proposed rule would result in outpatient revenue declines for safety-net, large urban and major teaching hospitals and gains for for-profit hospitals.

  4. Part of the payment increase for outpatient services will be offset by a separate cut: CMS will pay 2% less for nondrug outpatient services in 2027, up from 0.5% in 2026, to recover $7.8 billion in overpayments to hospitals from 2018 to 2022. Hospitals that enrolled in Medicare after Jan. 1, 2018, are exempt.

  5. Starting Jan. 1, hospitals must label every separately payable drug claim with one of three modifiers: JG for 340B drugs subject to the cut, TB for pass-through drugs and drugs administered at exempt hospitals, and ND for drugs purchased outside 340B.

    CMS declined requests to delay the requirement but noted hospitals have 12 months after the date of service to file claims.

  6. The 340B cut will reduce Medicare patients’ out-of-pocket costs, as they typically pay 20% of the Medicare-approved amount for a drug. CMS estimates patients who receive a 340B drug in a hospital outpatient department will save about $900 on average in 2027.

  7. Under the new rule, Medicare will pay off-campus hospital departments 40% of the standard hospital outpatient rate for imaging without contrast, including CT, MRI, ultrasound, X-ray and bone density scans.

    Rural sole community hospitals are the only exception to the lower rate, with CMS declining to exempt oncology-related imaging. The lower rate will apply to the 11 prospective payment system-exempt cancer hospitals, though CMS said losses will be offset through a separate year-end payment adjustment.

  8. As part of the Health Resources and Services Administration’s 340B Rebate Model Pilot Program, 340B hospitals will be required to pay the full wholesale price for 21 drugs from 10 drugmakers — including cancer drugs Ibrance, Imbruvica, Pomalyst and Xtandi — before receiving a rebate. Hospitals will have 45 days after dispensing a drug to submit a rebate claim, which drugmakers must then pay or deny within 10 days.

    The American Hospital Association, the Maine Hospital Association and four safety-net hospitals sued Oct. 9 to block the pilot, arguing it could cost hospitals more than $1 billion a year in administrative costs, compared with HHS’ estimate of $537 million.
Advertisement

Next Up in Pharmacy

Advertisement